Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Oct;77(10):1177-9.
doi: 10.1136/jnnp.2005.078345.

The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy

D M Bonifati  1 , S F Witchel, M Ermani, E P Hoffman, C Angelini, E Pegoraro
Affiliations

The glucocorticoid receptor N363S polymorphism and steroid response in Duchenne dystrophy

D M Bonifati et al. J Neurol Neurosurg Psychiatry. 2006 Oct.

Abstract

Background: Steroid administration is beneficial in Duchenne muscular dystrophy (DMD), but the response, incidence, and the severity of side effects are variable.

Aims: To investigate whether glucocorticoid receptor (GRL) gene polymorphisms may be responsible for glucocorticoid sensitivity in DMD.

Methods: Forty eight DMD patients treated either with prednisone or deflazacort were subjected to genetic analyses of the GRL gene.

Results: Mutation studies revealed an heterozygous A to G mutation at GRL cDNA position 1220 in three DMD patients resulting in an asparagine to serine amino acid change at amino acid position 363 (N363S). The N363S carrier DMD patients showed a trend towards a later age at loss of ambulation in comparison with non-carrier patients.

Conclusions: These data suggest that the N363S GRL polymorphism may be implicated in the long term response to glucocorticoids.

PubMed Disclaimer

Conflict of interest statement

Competing interests: none.

Comment in

  • Predicting steroid response in muscle disease.
    Nirmalananthan N, Hanna MG. Nirmalananthan N, et al. J Neurol Neurosurg Psychiatry. 2006 Oct;77(10):1104-5. doi: 10.1136/jnnp.2006.087874. J Neurol Neurosurg Psychiatry. 2006. PMID: 16980654 Free PMC article.

References

    1. Allsop K G, Ziter F A. Loss of strength and functional decline in Duchenne Dystrophy. Arch Neurol 198138406–411. - PubMed
    1. Dubowitz V. The muscular dystrophies. In: Dubowitz V, ed. Muscle disorders in childhood. London, Philadelphia and Toronto: Saunders, 199538–48.
    1. Drachman D B, Toyka K V, Myer E. Prednisone in Duchenne muscular dystrophy. Lancet 197421409–1412. - PubMed
    1. Brooke M H, Fenichel G M, Griggs R C.et al Clinical investigation of Duchenne muscular dystrophy: interesting results in a trial of prednisone. Arch Neurol 198744812–817. - PubMed
    1. Fenichel G M, Florence J, Pestronk A.et al Long‐term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991411874–1877. - PubMed

Publication types